FDA Greenlights Glaukos’ Breakthrough Eye Therapy for Corneal Disease

The U.S. Food & Drug Administration (FDA) has approved a new therapy from Glaukos Corporation, offering a less painful treatment for a rare eye condition called keratoconus. 

Keratoconus causes the cornea to thin and bulge, which leads to vision loss if untreated. Glaukos’ new topical therapy aims to treat this condition without the need for invasive surgery. 

The approval is based on successful late-stage trials involving more than 400 patients. The therapy met its main goals and showed a good safety profile. 

Glaukos expects to launch the therapy in the first quarter of 2026. The company’s stock rose following the approval. 

This marks a significant step for patients with keratoconus, particularly those under 30 who face a high risk of severe vision impairment. With the new option, they may avoid painful procedures and preserve eyesight more effectively.